Please login to the form below

Not currently logged in

Lilly's Strattera patent upheld in US

The US court of appeals has upheld the validity of Eli Lilly & Company's patent for ADHD drug Strattera

The US court of appeals has upheld the validity of Eli Lilly & Company's patent for attention deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine).

The decision overturns a previous ruling by a judge that Lilly's patent on the medicine was invalid, potentially opening the market to generic competition.

However, the most recent decision upholds Lilly's method-of-use patent which provides protection for Strattera until May, 2017.

Companies looking to capitalise on the loss of patent with their own versions of atomoxetine included Sun Pharmaceutical, Novartis' Sandoz unit, Aurobindo Pharma and Glenmark Pharmaceuticals.

Robert A Armitage, senior vice president and general counsel for Lilly, commented on the appeal: "In overturning the prior district court ruling, we believe that the Court fairly applied long-standing patent law principles."

1st August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...